A new treatment protocol that delivers a larger dose of AAV2-neurturin to the putamen, as well as directly to the substantia nigra, is currently being tested in a new randomized, sham-controlled, phase II trial of approximately 52 Parkinson's disease patients at 11 U.S. centers. The new treatment protocol was successfully given to six patients with Parkinson's disease in a phase I trial and has not been associated with any serious adverse events after 7-13 months of follow-up, according to Ceregene.
The new phase II trial of AAV2-neurturin is partially funded by the Michael J. Fox Foundation.
Jeff Evans contributed to this report.